|
January 16, 2013
|
|
||
|
Date of Report (Date of earliest event reported)
|
|
||
|
NU SKIN ENTERPRISES, INC.
|
|
||
|
(Exact name of registrant as specified in its charter)
|
|
||
Delaware
|
|
001-12421
|
|
87-0565309
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification Number)
|
|
75 West Center Street
Provo, UT 84601
|
|
||
|
(Address of principal executive offices and zip code)
|
|
||
|
(801) 345-1000
|
|
||
|
(Registrant's telephone number, including area code)
|
|
||
|
N/A
|
|
||
|
(Former name or former address, if changed since last report)
|
|
□ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
□ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c)) |
99.1 | Nu Skin Enterprises' press release dated January 16, 2013, regarding financial results for the fourth quarter and year ended December 31, 2012. |
99.1 | Nu Skin Enterprises' press release dated January 16, 2013, regarding financial results for the fourth quarter and year ended December 31, 2012. |
99.2 | Nu Skin Enterprises' investor presentation dated January 17, 2013. |
·
|
estimates and guidance concerning anticipated revenue, earnings per share and the impact of foreign currency are preliminary estimates, and actual results may differ from the estimates and guidance provided based on a number of factors, including higher than anticipated expenses, changes in reserves, and year-end and other financial statement or audit adjustments;
|
·
|
the actual declaration and payment of the planned dividends by the Board of Directors is subject to any changes in the company's net earnings, financial condition, cash requirements, future prospects or other factors deemed relevant by the company's board of directors that could cause the Board of Directors to reduce or discontinue the payment of currently planned quarterly dividends;
|
·
|
any failure of current or planned initiatives or products to generate interest among distributors and customers and generate sponsoring and selling activities on a sustained basis;
|
·
|
risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support our planned initiatives or launch strategies, including possible ingredient supply limitations;
|
·
|
challenging economic conditions globally;
|
·
|
risk of foreign currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
|
·
|
risks associated with general inquiries and complaints to consumer protection agencies in Japan regarding the activities of some distributors;
|
·
|
regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit the company's ability to import or continue selling a product in a market if it is determined to be a medical device or if it is unable to register the product in a timely manner under applicable regulatory requirements;
|
·
|
continued regulatory scrutiny and investigations in Mainland China, which have from time to time in the past, and could in the future, negatively impact the company's business, including the interruption of sales activities in stores, loss of licenses, and the imposition of fines;
|
·
|
adverse publicity related to the company's business, products, industry or any legal actions or complaints by distributors or others;
|
·
|
any prospective or retrospective increases in duties on the company's products imported into the company's markets outside of the United States and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; and
|
·
|
continued competitive pressures in the company's markets.
|
H^M1JC`\L2.P_R/7/2BS7DU;2S7;;73
MY_B1RZK6W5:>G_`WOTU?1-K+R#_^K\:>!D?/D^@Z8_S]*>48G@X&,\CWZ=.N
M*4#U#?@*=DK/1R>M^NR^Y]_^'&F[WN[:6NEK?[O72^B(V.WGKVQ_D4J`$]-I
M/U.]#OI]Z[MNVW=_UV!JW+MH]-&[[:
M^;^ZY%@CIT[#U]>3Z?C3^N>..H]O\:>0"@7*Y'?CU]_\YI#D[0<]>XQ^7'YT
MK2?RLM=-/*^W3[_,>ZWMJM7I=:/3?6ZT^:TU0BCJ2"<9.><<<@8]?>E(R-V,
M?CG.3^F/I2Y((4D[>W3Z